a,f,g,M Objectives: For both HIV-1 and hepatitis C virus (HCV), assessing the stringency of the transmission process is a scientific priority. Enumerations of transmitted/founder (TF) viruses have shown a strict transmission bottleneck in sexual transmission of HIV-1 and a wide range in the multiplicity of infection in HCV. Here, we aim to determine the stringency of parenteral transmission for HIV-1 and HCV in people who inject drugs (PWID).
HIV-1 and hepatitis C virus selection bottleneck in
Chinese people who inject drugs For both HIV-1 and hepatitis C virus (HCV), it is believed that preventive methods, including vaccines, will be most effective in blocking the virus or virus-infected cells at or near the moment of transmission or in early infection preceding systemic dissemination [1, 2] . Thus, understanding the earliest events of transmission and early infection are key to curbing these pandemics. To this end, the enumeration of transmitted/founder (TF) viruses has allowed quantification of the stringency of the selection bottleneck and highlighted differences between modes of transmission [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Both HIV-1 and HCV can be transmitted via sexual and parenteral transmission. For HIV-1, the more than 60 million infections comprising the global pandemic have been primarily sexual transmissions, but injection drug use accounts for nearly 10% globally [18] . An estimated 71 million individuals are living with HCV infection globally [19] , largely driven by parenteral exposure via IDU, contaminated blood supplies or medical equipment; sexual transmission has played a more minor role [20] .
Recent studies have consistently shown that mucosal transmission of HIV-1 is defined by a highly stringent bottleneck, with analyses of heterosexual transmission demonstrating the vast majority (>80%) of infections resulting from a single TF virus [3] [4] [5] . HIV-1 transmission in MSM is biologically and epidemiologically distinct from heterosexual transmission [21, 22] and studies of HIV-1 transmission in MSM show more frequent multivariant transmission (MVT) and a greater range in the number of TF viruses than heterosexuals [6] [7] [8] .
HIV-1 transmission in people who inject drugs (PWID) is expected to involve different biology than mucosal transmission. The specific target cells, immune pressures and inoculum size of parenteral transmission are unclear, but the physical barrier and immune functionalities comprising the mucosal transmission process are absent. A study of high-risk PWID in Montreal demonstrated a high rate of MVT, with examples of very high numbers of TF viruses in one individual [9] . Similarly, a study using single genome sequencing (SGS) to elucidate the failure of postexposure prophylaxis after a high-inoculum needlestick demonstrated the transmission of multiple (>15) TF viruses [23] . In contrast, studies of lower risk cohorts (e.g. PWID enrolled in drug treatment or clinical trials) have reported rates of MVT that are only marginally higher than in heterosexuals [10, 11] . Thus, the frequency of MVT in PWID is unclear.
For HCV infection, recent studies in acutely HCVinfected plasma donors have employed molecular sequencing and modelling to characterize HCV transmission and early virus diversification [12] [13] [14] [15] [16] . These studies revealed a wide range frequency of MVTestablishing HCV infection. Notably, the individuals studied either lacked reliable behavioural data, so the causative modes of transmissionincluding injection and sexual contact among MSMremain undefined. Molecular characterization of transmission processes for parenteral acquisition of these pathogens is, therefore, a scientific priority, especially in cohorts with characterized behaviours.
Our study aims to quantify the HIV-1 and HCV transmission bottleneck in a well characterized cohort of PWID in China.
We specifically ask what is the rate of MVT in PWID, how do HIV-1 and HCV transmission rates compare in the same cohort, and can we link any specific behaviours to MVT? We studied PWID from Urumqi, the capitol city of Xinjiang Province, which has a high prevalence of both infections [24, 25] . All study individuals were participants of HIV Prevention Trials Network (HPTN) studies in Urumqi between 2003 and 2012 [26, 27] , who were HIV-1 seronegative upon entry, provided detailed demographic and behavioural data, and then were followed longitudinally for HIV-1 and HCV seroconversion. Using SGS, validated models of early virus diversification and a Bayesian model of virus evolution, we provide the first description of the stringency of both the HIV-1 and HCV selection bottlenecks in a large, well described cohort of PWID.
Materials and methods

Ethics statement
This study was approved by the institutional review boards of the Chinese National Center for AIDS/STD Control and Prevention, the Chinese Center for Disease Control and Prevention, and the University of Pennsylvania. All study participants provided written informed consent prior to sample collection through HPTN033 and HPTN058, which were reviewed and approved by the China CDC and the Johns Hopkins IRBs [25, 27] .
Hepatitis C virus and HIV-1 testing HCV and HIV-1 infected individuals were identified by prospective serological testing during the HPTN trials; acute infection was determined by retrospective testing for vRNA in stored preseroconversion plasma. The HIV-1 samples were classified by Fiebig staging [28] . The window period of HCV seroconversion was estimated at 56 days [29] .
Viral RNA extraction, cDNA synthesis and SGS Viral RNA was extracted from plasma using the QIAamp Viral RNA Mini kit (Qiagen, Valencia, California, USA) and reverse transcribed by SuperScript III (Invitrogen, Carlsbad, California, USA). Full-length HIV-1 gp160 or gp41 and 5' half HCV genome sequences ranging from the complete half genome to a more than 1000 nucleotide amplicon were amplified by nested PCR from cDNA (primers in Table S1 , http://links.lww.com/QAD/ B194). SGS was carried out as previously described [5, 9] ; PCR products were sequenced by using BigDye Terminator chemistry (Applied Biosystems, Foster City, California, USA) and edited using Sequencher, version 4.7 (Gene Codes, Ann Arbor, Michigan, USA). All sequences were aligned using Gene Cutter (http:// www.hiv.lanl.gov/) and adjusted manually with Bioedit software [30] . All sequences were deposited in GenBank under accession numbers KY345421-KY346492, KY405041-KY405825.
Sequence analysis
A clustering approach also used for estimating numbers of linage variants. Within-individual nucleotide sequence diversity was analysed using DIVEIN [31] (http://indra. mullins.microbiol.washington.edu/DIVEIN). Sequences were visualized in Highlighter plots [5] . Neighbourjoining (NJ) phylogenetic trees were generated by Mega 6.0 [32] . Maximum likelihood (ML) phylogenies of all sequences for HIV-1 and HCV were generated by RaxML [33] . Sequences were assessed for fit to a model of random virus evolution by Poisson-Fitter (www.hiv. lanl.gov) [34] .
Mutation rate estimation and Bayesian analysis
Mutation rates for HIV-1 and HCV were calculated using Treerate (www.hiv.lanl.gov) with longitudinal sampling from our cohort and other acute infection cohorts [5, 35, 36] . Average mutation rates based on published estimates [37, 38] , of 1.7e À5 (HIV-1 gp160), 1.2 e
À5
(HIV-1 gp41) and 2.2e À5 (HCV) [39] substitutions/site/ day, were used in Bayesian analyses. The time since the most recent common ancestor (tMRCA) was estimated using a Bayesian Markov Chain Monte Carlo (MCMC) approach, implemented in BEAST v1.8.2 [40, 41] . All analyses were carried out using the HKY85 substitution model with gamma-distributed rate heterogeneity (four gamma categories), selected jModelTest 2.1.7 [42, 43] . We assumed exponential population growth and a strict molecular clock [34] . The MCMC algorithm was run for at least 10 8 generations (logging every 1000 generations; burn in was set to 10% of the original chain). The results were visualized in TRACER V1.6 [44] .
Results
Study population and clinical staging of samples
The present study analysed plasma samples collected in Urumqi, Xinjiang, through the HPTN033 and HPTN058 clinical studies [25, 27] . (Tables  1 and 2 , S2-3, http://links.lww.com/QAD/B194) [28] .
Clinical and behavioural characterization
In both HPTN033 and HPTN058, the HCV prevalence at enrolment was high (79 and 81% seropositivity, respectively) [25, 27] . The annual incidence of HCV was 52% during HPTN033 and 32% during HPTN058. Incidence also fell for HIV-1; it was 8.8% in HPTN033 and less than 2% in HPTN058 [18, 36] . We studied 33 participants with incident HIV-1 and 27 participants with incident HCV. Baseline demographic and behavioural data of these two subgroups are summarized in Table 3 . Briefly, participants were an average of 28 years, predominantly men and of Uyghur ethnicity, more likely to be single and without secondary or postsecondary education. Behaviourally, all reported active injection of heroin with the modal frequency of at least daily; a minority (28%) reported sharing injection equipment. The majority were sexually active with a minority, 22%, reporting multiple partners. We have no data on the sex of individual's partners, nor self-reports of MSM activity.
Sequence analyses of HIV-1 primary infections
We generated 1070 SGS-derived HIV-1 env sequences (median 30 per individual, range 14-71). For 22 individuals, full env gp160 regions were sequenced; for 11 individuals, gp41 sequences were generated (Table 1) . When the gp41 sequences of the 33 HIV infections were analysed together in a maximum likelihood phylogeny, each individual's sequences clustered independently, with the exception of three groups of linked infections (Fig. S1, http://links.lww.com/QAD/B194). The limited genetic distance between nodes reflects the homogeneity of the CRF07_BC epidemic and closely related networks of PWID in Urumqi [45, 46] .
For the 33 HIV-1 seroconversions, we enumerated TF viruses through several methodologies, including visualization of highlighter plots and phylogenies, Poisson-fitter modelling [34] and comparison with Bayesian estimations of time to tMRCA (Table 1 ). Four representative examples are shown in Fig. 1 . Individual 33.12 ( Fig. 1a) , sampled in Fiebig stage II, had a homogeneous sequence set with a maximum diversity of 0.002 that formed a single low-diversity lineage in both the Highlighter plot and the NJ tree. Poisson-Fitter modelling suggested a single virus transmission (SVT) ( Table 1 Sequence analyses of hepatitis C virus seroconversions A total of 773 HCV 5' half genome sequences (median 27 per individual, range 11-57) were generated by SGS. When sufficient numbers of complete half genomes were not obtained or when plasma samples were limited, we amplified shorter regions within the 5' half genome (between 700 and 4879 nucleotides) ( Table 2 ). Virus subtype was determined for each sample; we detected the predominant genotypes reported to be circulating in Xinjiang (3a, 3b and 1b) [42] . When analysed within a maximum likelihood phylogeny with reference sequences, the sequences clustered by genotype with strong bootstrap support and individual participants' sequences formed distinct, but closely related lineages, reflecting a narrow genetic range of the Xinjiang HCV epidemic in PWID [24] .
Individual participant lineages demonstrated a substantial range in maximum within-patient diversity, from 0.0005 to 0.093 (Table 2) . To determine the multiplicity of HCV infection, we visualized sequences by NJ phylogeny and Highlighter plot and analysed the sequences with PoissonFitter, a model of random virus evolution that has been validated in early HCV infection [13, 35] . Four representative individuals' sequences are shown in Figs. 1 illustrated by participants 58.19 and 58.16 ( Fig. 2c and d) , had greater sequence diversity (0.0068-0.093) that clustered into multiple lineages by NJ phylogeny and Highlighter plot. In these individuals, tMRCA preceded the maximum time since infection, suggesting MVT ( Table 2 ). Enumeration of low-diversity lineages in NJ and MCC phylogenies demonstrated between two and six genetically distinct virus populations in these individuals with MVT. In total, we found 52% (14 of 27) MVT of HCV, with a range of two to six virus lineages per participant.
To mitigate concerns about the effects of immune selection in HCV infection after nearly 80-100 days [14] [15] [16] , we performed analyses excluding all individuals sampled postseroconversion. Restricting the analysis to only HCV transmissions sampled in acute infection (preseroconversion), the frequency of MVT is similar, with 47% (9/19) MVT and a range of two to six TF variants.
In summary, we found between 47 and 52% (14/27 or 9/ 19) MVTof HCV, with a range of two to six virus lineages per individual.
Correlations between clinical and behavioural data and multivariant transmission We performed multivariate analysis for risk factors associated with MVT in both HCV and HIV-1 seroconversions. We assessed demographic characteristics, including age, sex, education level and marital status, and risk behaviours, including shared needles and equipment, practices such as backloading and drug type. In multivariate analyses of both HIV-1 and HCV, no demographic characteristics or drug or sexual behaviours were significantly correlated with MVT (Table S4 , http://links.lww.com/QAD/B194).
Discussion
The present study provides new insights into the transmission of HIV-1 and HCV in PWID. Using multiple complementary sequence analysis strategies, we determined the stringency of the transmission process in well described cohorts of Chinese PWID for these two critically important viral pathogens.
For HIV-1, we found a rate of 39% MVT, which suggests a substantially more permissive transmission process in parenteral transmission than in sexual transmission (Table  S5 , http://links.lww.com/QAD/B194) [3] [4] [5] [6] [7] [8] . For HCV, results provide the first estimate of the multiplicity of infection specifically in PWID. We found 47% MVT in preseroconversion HCV infections and 52% in both acute and early HCV infections in the Xinjiang PWID.
The increased frequency of MVT in PWID compared with mucosal transmission cohorts is important for several reasons. First, it suggests a distinct biology of transmission in parenteral exposures that is congruent with the higher epidemiologic risk of infections in parenteral exposure. Similar rates of MVT have been seen in analyses of other cohorts, and our findings support and strengthen this body of evidence. Including our study, analysis of 75 total PWID using similar methodologies yields a rate of 43% MVT in HIV-1 (Table S5 , http://links.lww.com/QAD/ B194). That the frequency of MVT is similar in studies performed in different geographical regions, with diverse virus subtypes [9] [10] [11] , and in cohorts with different risk behaviours provides additional confidence to the idea that parenteral transmission is a significantly more permissive process than is sexual transmission in both heterosexual cohorts (18-9% MVT, P ¼ 0.0003, Fisher's exact test) and MSM (25% MVT, P ¼ 0.0123) Table S5 , http:// links.lww.com/QAD/B194). Notably, we did not find examples of very high numbers of TF viruses in our cohort, as has been reported in high-risk PWID [9] , large inocula parenteral exposures [23] or other studies of HCV transmission [13] . This may be due to later sampling and limited sampling depth, but we note the high numbers of TF viruses seen in the cited examples persisted through early infection when tested [9, 13, 23] . Our quantitative measure of the HCV selection bottleneck in PWID is, to our knowledge, the first study to link a sensitive molecular estimate of the multiplicity of HCV infection with a mode of transmission in larger cohort of individuals. Unique to our study, the virologic measures are linked to behavioural data. All individuals reported ongoing injection practices with minimal sexual risk factors (just 22% reported multiple partners). Although we found no clear associations between any specific behaviours and MVT, the behavioural data allow us to more clearly establish the link between injection and increased multiplicity of infection.
Our results also have clinical implications. MVTof HIV-1 has been shown to be associated with worse virologic and clinical outcomes in large cohorts [49, 50] . In conjunction with the detrimental effects of injection drug use unrelated to HIV-1 and HCV [51] [52] [53] , these data inform our understanding of the health challenges of PWID.
Finally, a less stringent transmission process has important theoretical consequences for prevention strategies, wherein interdiction of MVT may be more challenging than SVT. Recent analyses of acute and early infection suggest that MVT may allow the virus greater flexibility to rapidly escape host immune pressures [54] . In theory, therefore, the efficacy of preventive strategies, for example vaccines or preexposure prophylaxis with antiretroviral medications, may need to be independently evaluated in individuals with predominantly parenteral transmission risks.
This study also provided the unique opportunity to compare the multiplicity of infection of both HIV-1 [24, 25, 27, 55] . While many factors likely contributed to the differential decrease in HIV-1 compared with HCV, it is reasonable to infer that the prevention strategies in place, including treatment with buprenorphine/naloxone combined with behavioural drug and risk counselling [27] , while associated with a reduction in incident HIV-1, were insufficient to greatly impact the local HCV epidemic. Further study into coinfected individuals to investigate these issues is warranted.
This study had several important limitations inherent to the use of this cohort and our chosen methods. First, some individuals had samples obtained after antibody seroconversion. Although it is challenging to identify the exact sequence of the TF viruses, we argue it is feasible to infer a minimal estimate of the diversity at transmission using the novel Bayesian model of virus evolution as both HIV and HCV, which utilizes exponential viral growth with sequence diversity increased linearly within $150 days after infection [56] [57] [58] . Using this strategy, we can confidently determine a threshold diversity in which SVT was not possible. In addition, later sampling prevented the opportunity to sequence some HCVinfected individuals who spontaneously cleared infection in the interval before sampling. To mitigate effects of later sampling our sequence analyses, we assessed virus evolution by multiple methods. Importantly, the Bayesian, Poisson-Fitter and phylogenetic estimates of the minimum number of virus lineage were highly congruous (Tables 1 and 2 ) and comparisons of HCV infections studied before and after seroconversion led to similar estimates of the frequency of MVT and the range of TF viruses. An additional limitation of the study is that our enumeration of virus lineages are minimum estimates, as our methods may have underestimated minor variants and closely related variants [5, 6] . The sensitivity to detect minor variants is directly related to sequencing depth; given the median numbers of sequences for HIV-1 and HCV (30 and 27, respectively), we have 95% confidence of detect variants circulating at least nearly 10% frequency, and may miss more minor constituents [5] . Further, the later sampling limited discrimination of multiple closely related variants, which can only be distinguished when acutely infected individuals are sampled extremely early in infection [5, 12, 13, 34] . Another limitation was sample degradation, which precluded amplification of full env genomes (HIV-1) or complete 5' half genomes (HCV) in several participants. We performed sensitivity analyses to determine the ability to estimate tMRCA with larger (between 3 and 5 kB) and smaller ($1 kB) sequence spans and found only minor differences between sequence lengths (Table S6 , http://links.lww.com/ QAD/B194).
In summary, we found a relatively permissive transmission bottleneck to both HIV-1 and HCV in PWID in Xinjiang, China. The estimations of the multiplicity of infection in PWID provide a quantitative measure of the HIV-1 and HCV transmission process in this critically important population. Results provide an estimate of the challenge to be overcome by preventive strategies needed to end these pandemics.
